ATE405661T1 - G protein-verwandte kinasemutanten in der essentiellen hypertonie - Google Patents
G protein-verwandte kinasemutanten in der essentiellen hypertonieInfo
- Publication number
- ATE405661T1 ATE405661T1 AT99902201T AT99902201T ATE405661T1 AT E405661 T1 ATE405661 T1 AT E405661T1 AT 99902201 T AT99902201 T AT 99902201T AT 99902201 T AT99902201 T AT 99902201T AT E405661 T1 ATE405661 T1 AT E405661T1
- Authority
- AT
- Austria
- Prior art keywords
- essential hypertension
- present
- protein
- related kinase
- kinase mutants
- Prior art date
Links
- 208000007530 Essential hypertension Diseases 0.000 title abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000003276 anti-hypertensive effect Effects 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000007876 drug discovery Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 210000003292 kidney cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7119998P | 1998-01-12 | 1998-01-12 | |
| US9827998P | 1998-08-28 | 1998-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE405661T1 true ATE405661T1 (de) | 2008-09-15 |
Family
ID=26751950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99902201T ATE405661T1 (de) | 1998-01-12 | 1999-01-12 | G protein-verwandte kinasemutanten in der essentiellen hypertonie |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6660474B1 (de) |
| EP (2) | EP2009109A1 (de) |
| JP (2) | JP4652566B2 (de) |
| AT (1) | ATE405661T1 (de) |
| AU (1) | AU2223899A (de) |
| CA (1) | CA2318479C (de) |
| DE (1) | DE69939367D1 (de) |
| DK (1) | DK1045918T3 (de) |
| WO (1) | WO1999035279A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002035923A1 (en) * | 2000-10-31 | 2002-05-10 | Duke University | Hypertension |
| WO2002103020A1 (en) * | 2001-06-15 | 2002-12-27 | Takeda Chemical Industries, Ltd. | Novel disease-associated gene and use thereof |
| AU2002358267A1 (en) * | 2001-12-19 | 2003-07-09 | Millennium Pharmaceuticals, Inc. | Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| WO2005093096A1 (es) * | 2004-03-29 | 2005-10-06 | Universitat Pompeu Fabra | Método y kit para la detección del riesgo de padecer hipertensión |
| WO2005114195A1 (en) * | 2004-05-21 | 2005-12-01 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 4 (grk4) |
| CN100465288C (zh) * | 2005-08-10 | 2009-03-04 | 中国医学科学院阜外心血管病医院 | 检测与人类原发性高血压相关的grk4基因多态的方法 |
| US20080268442A1 (en) * | 2007-04-24 | 2008-10-30 | Igd Intel, Llc | Method and system for preparing a blood sample for a disease association gene transcript test |
| US8135545B2 (en) | 2007-11-09 | 2012-03-13 | Iverson Genetic Diagnostics, Inc. | System and method for collecting data regarding broad-based neurotoxin-related gene mutation association |
| US20090125244A1 (en) * | 2007-11-09 | 2009-05-14 | Igd Intel Llc | Broad-based neurotoxin-related gene mutation association from a gene transcript test |
| WO2014108449A1 (en) | 2013-01-08 | 2014-07-17 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| US9657348B2 (en) | 2013-01-13 | 2017-05-23 | Atrogi Ab | Method of screening compounds for the treatment of diabetes |
| WO2015090350A1 (en) | 2013-12-16 | 2015-06-25 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| CN105296488B (zh) * | 2015-12-02 | 2018-05-01 | 中国人民解放军第三军医大学第三附属医院 | 超声微泡介导的siRNA干扰GRK4在靶向调节尿钠排泄及血压水平中的应用 |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| CN107881226A (zh) * | 2017-10-30 | 2018-04-06 | 广东药科大学 | Scad基因或scad蛋白在制备防治血管重构和重大血管疾病药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| ATE132266T1 (de) | 1987-05-01 | 1996-01-15 | Stratagene Inc | Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten |
| US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
| US5098890A (en) | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| US5135917A (en) | 1990-07-12 | 1992-08-04 | Nova Pharmaceutical Corporation | Interleukin receptor expression inhibiting antisense oligonucleotides |
| US5288846A (en) | 1990-10-19 | 1994-02-22 | The General Hospital Corporation | Cell specific gene regulators |
| DE4126968A1 (de) | 1991-08-14 | 1993-02-18 | Detlev Prof Dr Med Ganten | Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist |
| US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
| DE69233109T2 (de) | 1992-01-07 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Transgene tiermodelle fur alzheimer-krankheit |
| EP0663952A4 (de) | 1992-09-11 | 1997-06-11 | Univ California | Transgene nicht-humane tiere mit zielgerichtet unterbrochenen transduktionsgenen in lymphozyten. |
| WO1994013303A1 (en) | 1992-12-14 | 1994-06-23 | Start Technology Partnership | Administration of oligonucleotides antisense to dopamine receptor mrna for diagnosis and treatment of neurological pathologies |
| WO1994023049A2 (en) | 1993-04-02 | 1994-10-13 | The Johns Hopkins University | The introduction and expression of large genomic sequences in transgenic animals |
| US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
| US5856103A (en) | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5834248A (en) | 1995-02-10 | 1998-11-10 | Millennium Pharmaceuticals Inc. | Compositions and methods using rchd534, a gene uregulated by shear stress |
| NO953680D0 (no) | 1995-09-18 | 1995-09-18 | Hans Prydz | Cellesyklusenzymer |
| KR19990071523A (ko) | 1995-11-21 | 1999-09-27 | 해리 에이. 루스제 | Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법 |
| US5856099A (en) | 1996-05-21 | 1999-01-05 | Isis Pharmaceuticals, Inc. | Antisense compositions and methods for modulating type I interleukin-1 receptor expression |
-
1999
- 1999-01-12 JP JP2000527662A patent/JP4652566B2/ja not_active Expired - Fee Related
- 1999-01-12 DK DK99902201T patent/DK1045918T3/da active
- 1999-01-12 DE DE69939367T patent/DE69939367D1/de not_active Expired - Lifetime
- 1999-01-12 EP EP08162553A patent/EP2009109A1/de not_active Withdrawn
- 1999-01-12 WO PCT/US1999/000663 patent/WO1999035279A1/en active Application Filing
- 1999-01-12 AU AU22238/99A patent/AU2223899A/en not_active Abandoned
- 1999-01-12 AT AT99902201T patent/ATE405661T1/de not_active IP Right Cessation
- 1999-01-12 CA CA002318479A patent/CA2318479C/en not_active Expired - Fee Related
- 1999-01-12 EP EP99902201A patent/EP1045918B1/de not_active Expired - Lifetime
-
2000
- 2000-07-12 US US09/614,748 patent/US6660474B1/en not_active Expired - Lifetime
-
2003
- 2003-10-02 US US10/677,983 patent/US20050089871A1/en not_active Abandoned
-
2008
- 2008-12-01 US US12/315,338 patent/US9074016B2/en not_active Expired - Fee Related
-
2010
- 2010-09-06 JP JP2010199161A patent/JP5340242B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2318479A1 (en) | 1999-07-15 |
| EP1045918B1 (de) | 2008-08-20 |
| JP4652566B2 (ja) | 2011-03-16 |
| CA2318479C (en) | 2009-03-24 |
| EP1045918A4 (de) | 2003-10-08 |
| EP2009109A1 (de) | 2008-12-31 |
| US9074016B2 (en) | 2015-07-07 |
| JP2002508157A (ja) | 2002-03-19 |
| US20100313286A1 (en) | 2010-12-09 |
| JP5340242B2 (ja) | 2013-11-13 |
| US6660474B1 (en) | 2003-12-09 |
| DE69939367D1 (de) | 2008-10-02 |
| DK1045918T3 (da) | 2008-12-08 |
| AU2223899A (en) | 1999-07-26 |
| EP1045918A1 (de) | 2000-10-25 |
| WO1999035279A1 (en) | 1999-07-15 |
| US20050089871A1 (en) | 2005-04-28 |
| JP2011036253A (ja) | 2011-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE405661T1 (de) | G protein-verwandte kinasemutanten in der essentiellen hypertonie | |
| CR7925A (es) | Tinturas de cianina hidrofilicas, reactivas con tiol y conjugados de las mismas con biomoleculas para diagnostico por fluorescencia | |
| ATE412891T1 (de) | Verbessertes toxizität-screening verfahren | |
| IL140622A0 (en) | Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| ATE248175T1 (de) | Epothilonderivate und ihre verwendung als antitumormittel | |
| DK1141137T3 (da) | Vandopløselige rhodaminfarvestoffer og konjugater deraf | |
| ATE37375T1 (de) | Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva. | |
| ATE273956T1 (de) | Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten | |
| EP1687283A4 (de) | Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung | |
| DE69806696T2 (de) | N,N',N''-Tris(2,4-Bis(1-Hydrocarbyloxy-2,2,6,6-tetramethylpiperidin-4-yl)alkylamino)-s-triazin-6-yl)-3,3'-ethylenediiminodipropylamine, ihre Isomere und überbrückte Derivate, sowie damit stabilisierte Polymerzusammensetzungen | |
| CY1107493T1 (el) | Μεθοδοι και συνθεσεις για την προληψη ανεκτικοτητας στα βρογχοδιασταλτικα | |
| BRPI0415361A (pt) | antagonistas do receptor muscarìnico de acetilcolina | |
| TR200102025T2 (tr) | Dopamin-D3-Reseptör afinitesine sahip triazol bileşikleri | |
| ATE301122T1 (de) | Kernerweiterte perylenbisimide und ihre verwendung als fluoreszenzfarbstoffe | |
| AU2001268449A1 (en) | Toxicity typing using liver stem cells | |
| CA2439222A1 (en) | Identification of partial agonists of the a2a adenosine receptor | |
| SE9702773D0 (sv) | Novel compounds | |
| EA200300593A1 (ru) | Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора | |
| EA200301100A1 (ru) | Новые фталазиноны | |
| BRPI0412716A (pt) | antagonistas de receptor muscarìnico de acetilcolina | |
| ATE296809T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
| ATE284407T1 (de) | Pyrimidinderivate als markierte bindungspartner | |
| BRPI0412679A (pt) | antagonistas de receptor muscarìnico de acetilcolina | |
| EA200200732A1 (ru) | Замещенные производные фенилпиперазина, их получение и применение | |
| EA200500830A1 (ru) | Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |